Targeting regulated cell death in tumor nanomedicines.

Qinghu Zeng, Xiangyi Ma, Yangmeihui Song, Qiqing Chen, Qiuling Jiao, Liqiang Zhou

Theranostics 2022

filter terms:

Nanomedicines hold great potential in anticancer therapy by modulating the biodistribution of nanomaterials and initiating targeted oxidative stress damage, but they are also limited by the inherent self-protection mechanism and the evolutionary treatment resistance of cancer cells. New emerging explorations of regulated cell death (RCD), including processes related to autophagy, ferroptosis, pyroptosis, and necroptosis, substantially contribute to the augmented therapeutic efficiency of tumors by increasing the sensitivity of cancer cells to apoptosis. Herein, paradigmatic studies of RCD-mediated synergistic tumor nanotherapeutics are introduced, such as regulating autophagy-enhanced photodynamic therapy (PDT), targeting ferroptosis-sensitized sonodynamic therapy (SDT), inducing necroptosis-augmented photothermal therapy (PTT), and initiating pyroptosis-collaborative chemodynamic therapy (CDT), and the coordination mechanisms are discussed in detail. Multiangle analyses addressing the present challenges and upcoming prospects of RCD-based nanomedicines have also been highlighted and prospected for their further strengthening and the broadening of their application scope. It is believed that up-and-coming coadjutant therapeutic methodologies based on RCDs will considerably impact precision nanomedicine for cancer. © The author(s).

Citation

Qinghu Zeng, Xiangyi Ma, Yangmeihui Song, Qiqing Chen, Qiuling Jiao, Liqiang Zhou. Targeting regulated cell death in tumor nanomedicines. Theranostics. 2022;12(2):817-841